Live from ClinicalTrials.gov + Open Targets, fetched 2026-11-11 16:19 UTC. Every row links to its source record.
Postmortem · what the sponsor and named sources said, kept apart from what merely happened at the same time
A Study of Intra-tumoral Administered MTX110 in Patients With Recurrent Glioblastoma
NCT05324501 · Biodexa Pharmaceuticals · PHASE1 · terminated · last registry update 2025-02-10 · Glioblastoma · Decision brief
No research has been run for this trial yet, so only the registry's own reason and the timeline are shown.
What was said, and by whom
Stated is the sponsor's own words; Reported is a named third party. The category is our label from a fixed list; the quote is the evidence.
| Kind | Quote | Our category | Source |
|---|---|---|---|
| Stated | “Strategic decision” | Open Targets' class: business administrative | Registry record, Biodexa Pharmaceuticals |
Also happening at the time. Not shown to be a cause.
Registry events on other trials of drugs against HDAC1 in glioblastoma within 12 months either side of this trial's last update, live from ClinicalTrials.gov. Nothing here was stated as a reason.
- 2025-10-06Results posted on the registry: H. Lee Moffitt Cancer Center and Research Institute, Pembrolizumab + Vorinostat (NCT03426891)
- 2024-08-22Results posted on the registry: M.D. Anderson Cancer Center, Vorinostat + Isotretinoin (NCT00555399)
- 2024-08-22Also stopped (terminated): M.D. Anderson Cancer Center, Vorinostat + Isotretinoin (NCT00555399)
What is not public
- Internal portfolio and board discussions
- Unpublished trial data and interim analyses
- Terms of any partner or licence decision